A Commentary on

Pørksen C J, Ekstrand K R, Markvart M, Larsen T, Garrido L E, Bakhshandeh A.

The efficacy of combined arginine and probiotics as an add-on to 1450 ppm fluoride toothpaste to prevent and control dental caries in children – A randomized controlled trial. J Dent 2023; 137: 104670.

GRADE Rating:

Commentary

The global burden of dental caries is extensive affecting more than one third of the world’s population1. Dental caries has an estimated prevalence of 43%, making it a major public health concern1. Caries is a multifactorial disease, influenced by factors including diet, oral hygiene and the oral environment. A range of public health guidelines have been developed, aimed at governments, dental health professionals and the general population. In England, the Department of Health and Social Care issued “Delivering better oral health: an evidence-based toolkit for prevention publication (2021)”2. These interventions focus on dietary changes, good oral hygiene practice and professional preventive interventions, such as regular topical fluoride application. Since its introduction in the late 1970s, the use of fluoridated toothpaste has been credited as the primary component in contributing to reduction of caries incidence3. Despite extensive investment in nationwide programmes such as “SMILE4LIFE” and “Starting Well Core: 0–2 s”, and the shift in focus to preventative dentistry, dental caries remains the most prevalent non-communicable disease worldwide1,4. In recent years, research has explored other topical or systemic products that may act as an adjunct to fluoride toothpaste by counteracting the demineralising activity of the caries microbiome and/or encouraging remineralisation, helping to reduce or slow caries progression and development3.

This randomised controlled trial (RCT) looks at the use of a combination of probiotics (Lacticaseibacillus rhamnosus and Lactobacillus paracasei subsp. paracasei) and a prebiotic as an adjunct to 1450 ppm fluoridate toothpaste. Oral bacteria metabolise arginine, resulting in the production of ammonia, thus raising the pH of the biofilm5. The probiotics act directly on the oral biofilm using a variety of mechanisms, such as bacteriocin production and growth inhibition to neutralise the effect of cariogenic bacteria6. This is a secondary analysis of data from a previously published trial by the same authors. This earlier trial demonstrated a statistically significant effect on caries increment with a lozenge combining prebiotic arginine and probiotics. This secondary analysis sought to focus on the effect of the same intervention on progression, arrest and regression of pre-existing caries lesions.

The aim of the study was to observe the efficacy of ingested arginine and probiotics on caries progression, regression and lesion activity at a tooth surface level over a period of 10–12 months. Participants’ parents completed a survey at baseline and follow up reviews to enable consideration of potentially confounding factors such as dietary habits; frequency of brushing, and parental education level. Both the investigators and participants were masked to allocation by the use of placebo pro/prebiotic capsules, to ensure that potential bias introduced by participant behavioural changes or caries detection by investigators was mitigated.

Because this is a secondary analysis of trial data, there is no power calculations for the outcomes reported. Therefore, findings should be interpreted with caution. The inclusion criteria are documented in the “main study”, requiring children to be medically fit and well, between the ages of 5 and 9 years and reside in one of the four described municipalities of Denmark5. Additionally, all participants were low caries risk. This may reduce the generalisability of the results and potential intervention to demonstrate a clinically important effect, although may have been a pragmatic decision to ensure a compliant, homogeneous participant cohort.

Although the investigators were trained and calibrated in the use of the original ICDAS scoring system, they were not calibrated for the use of the modified classifications used in this analysis7,8. Furthermore, the examiners excluded surfaces affected by molar-incisor hypoplasia (MIH) which could lead to an underestimation of caries progression as these are typically high-risk surfaces.

Compliance of ingestion of the lozenges was measured throughout the study, however they relied upon weekly and monthly electronic Patient Reported Outcomes. This is subject to reporting bias, as parents may have reported falsely elevated levels of compliance. The investigators considered adequate compliance to be consumption of the lozenges at least 5 days out of every 7 (~70%). Overall compliance was 87.5%, which is high. This highlights the importance of patient compliance. Of note, it might be expected that compliance rates may be lower in higher caries risk populations which may impact the effectiveness of the intervention.

Is there a gap in the market for pro- and prebiotics as an adjunct to fluoride? Ultimately, no significant difference was found between the intervention and placebo group in this study. Therefore, the surface level reduction in caries progression rate, increased regression rate and lower number of active carious lesions described by the authors should be interpreted with caution. While adjunctive prebiotic and probiotic lozenges show promise in reducing caries increment in low caries risk children, there is no apparent effect on pre-existing carious lesions. An adequately powered study in a high caries risk group may reveal over a longer time period may reveal further utility of adjunctive pro- and prebiotics in the management of caries.